Business ❯ Pharmaceuticals

Acquisitions

Drug Development Biotechnology Sanofi Eli Lilly Mergers and Acquisitions Merck Corporate Strategy Novartis Rare Diseases Oncology Biopharmaceuticals AbbVie Novo Nordisk Market Trends Bristol Myers Squibb Market Strategy Pfizer Merck & Co. Clinical Development BioNTech Biotech Companies Corporate Finance Immunology Cancer Treatment Vaccine Development Gene Therapy Vertex Pharmaceuticals Market Dynamics Clinical Trials Intellectual Property Zydus Lifesciences Organon & Co COVID-19 Impact Competition Private Equity Biopharma Obesity Treatments Biotech Icosavax Acquisition Icosavax First Wave BioPharma Inc AstraZeneca PLC Genmab AstraZeneca Cancer Treatments Market Valuation Genetics Genetic Testing Ophthalmology Biontech Data Privacy Merck Group Psychedelic Therapies JB Chemicals Biopharmaceutical Companies Psychedelic Treatments Generic Drugs Biopharma Industry Weight Loss Drugs Partnerships Biogen Obesity Drugs Merus Strategic Partnerships Regulatory Approval Company History Market Competition Mergers Financial Impact Vaccine Industry GSK Gilead Sciences Moderna Evotec Corporate Transactions Strategic Planning Teva Pharmaceuticals International Expansion Market Expansion Genetic Medicine Psychedelic Drugs Neuroscience Angelini Pharma Jazz Pharmaceuticals Corporate Growth

Lilly to Buy Merida Biosciences for Up to $2.875 Billion

The deal gives Lilly a precision antibody‑degradation platform and a Phase 1 candidate that cut disease‑driving antibodies, signaling a push to broaden its immunology pipeline.

BioMarin to Buy Alesta for $275 Million to Add Oral HPP Drug

Jazz Pharmaceuticals to Buy Actio Biosciences for $820 Million

Lilly to Acquire AtaiBeckley in Deal Valued Up to $3.8 Billion

Eli Lilly Agrees to Buy Psychedelic Biotech AtaiBeckley for $2.8 Billion

Vertex to Buy Crinetics for $10 Billion, Gaining Oral Endocrine Drugs

GSK to Buy Nuvalent for $10.6 Billion to Bolster Lung‑Cancer Pipeline

Lilly Agrees to Buy Three Vaccine Developers for Up to $3.8 Billion

Lilly Acquires Engage Biologics for Up to $202 Million

UCB to Buy Candid Therapeutics for Up to $2.2 Billion

LEO Pharma to Acquire Replay in $50 Million Gene-Therapy Deal

Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Blood Cancer Deal

Eli Lilly to Buy Kelonia for Up to $7 Billion to Gain In‑Vivo CAR‑T Platform

Lilly to Acquire Centessa for $6.3 Billion to Add Orexin Sleep Drugs

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug